Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide following dangerous brain inflammation in seven patients in Europe.

Biogen Inc.’s stock tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug fell ...

Biogen's efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China's InnoCare last year for $125 ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...

Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...